Oral semaglutide cut total heart events, not just first ones, in a diabetes trial
A prespecified analysis of the 9,650-patient SOUL trial counted recurrent as well as first cardiovascular events. Oral semaglutide lowered the total burden by about 14% against placebo.
| Group | Value (value) |
|---|---|
| Oral semaglutide | 683 |
| Placebo | 791 |
Most cardiovascular trials count only a patient's first major event — the first heart attack, stroke or cardiovascular death — and then, for the primary analysis, stop the clock. But patients who survive a first event remain at risk of more, and a treatment's full value includes the events it prevents second and third time round. A prespecified secondary analysis of the SOUL trial, published in JAMA Cardiology, applies that fuller accounting to oral semaglutide — and finds the benefit holds up [s1].
What the analysis did
SOUL was a double-blind, placebo-controlled, event-driven phase 3b trial conducted from June 2019 to September 2024, with a median follow-up of 49.5 months (interquartile range 44.0 to 54.9), across 444 centres in 33 countries [s1]. It enrolled people with type 2 diabetes who also had atherosclerotic cardiovascular disease, chronic kidney disease, or both [s1]. Participants were randomly assigned 1:1 to once-daily oral semaglutide, at a maximal dose of 14 mg, or to placebo, each added to standard care [s1]. The trial is registered as NCT03914326 [s2].
The original trial reported that oral semaglutide reduced the risk of a first three-point major adverse cardiovascular event — the composite of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death [s1]. This new analysis asked a different question: what is the effect on total events, first plus subsequent, which is a measure of the overall burden of disease rather than the timing of a first hit [s1]. In all, 9,650 participants were randomised; their median age was 66.0 years and 6,860 (71.1%) were male [s1].
What it found
Counting all events, there were fewer in the oral-semaglutide group: 683 total three-point MACE (579 first and 104 subsequent events) versus 791 in the placebo group (668 first and 123 subsequent) [s1]. The mean ratio was 0.86 (95% confidence interval 0.76 to 0.97; P=0.01) — roughly a 14% lower total event rate [s1].
A broader composite that added death from non-cardiovascular causes pointed the same way: 910 total events with oral semaglutide against 1,048 with placebo, 138 fewer, for a mean ratio of 0.87 (95% CI 0.79 to 0.95; P=0.004) [s1]. As previously reported, adverse events led to treatment discontinuation in 749 participants (15.5%) on oral semaglutide and 559 (11.6%) on placebo [s1].
How to read it
The value of a total-event analysis is that it reflects what a treatment does to the whole course of disease, not just to the first milestone — and here it reinforces, rather than revises, the trial's main conclusion [s1]. The direction and rough size of the benefit are consistent with the original first-event result, which is the reassuring pattern: the headline finding was not an artefact of where the clock stopped.
The caveats are the ordinary ones for an analysis of this kind. This is a secondary analysis, prespecified but still downstream of the trial's primary question, so it is best read as corroboration rather than a fresh, independent result [s1]. The subsequent-event counts are modest — 104 and 123 — so the total-event result is driven largely by first events, and the extra precision from counting recurrences is limited [s1]. The population was specifically high-risk — type 2 diabetes plus established cardiovascular or kidney disease — so the findings speak to that group, not to lower-risk patients [s1]. And the higher discontinuation rate on the drug is a reminder that tolerability shapes who stays on treatment long enough to benefit [s1].
What to watch
The questions that follow are whether total-event analyses like this one begin to feature in how regulators and guideline committees describe a drug's cardiovascular benefit, and how oral semaglutide's effect compares with the injectable version and with other agents in the same high-risk diabetic population. For now, the finding is narrow and solid: across the full count of events, oral semaglutide lowered the total burden of major cardiovascular events by about 14% against placebo in high-risk type 2 diabetes [s1].
This article describes clinical-trial results and is not medical advice. Decisions about diabetes and cardiovascular treatment should be made with a clinician.
Sources
- First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial — JAMA Cardiology , November 11, 2026
- A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL) (NCT03914326) — ClinicalTrials.gov
More on
A trial stopped early backs holding a GLP-1 dose before upper endoscopy
OCULUS was halted at interim analysis: continuing a GLP-1 or GIP agonist before endoscopy left 25.0% of patients with clinically significant retained stomach contents, versus 3.1% who held one dose.
Semaglutide improved walking distance in peripheral artery disease
In the phase 3b STRIDE trial, people with peripheral artery disease and type 2 diabetes walked 13% farther at 52 weeks than on placebo (treatment ratio 1.13; p=0.0004). The gain is modest; Novo Nordisk funded it.
Two GLP-1 pills went head to head. One won on blood sugar and lost on side effects.
ACHIEVE-3 randomised 1,698 people to orforglipron or oral semaglutide for 52 weeks. Orforglipron cut HbA1c more at every dose comparison — and produced more side effects and more dropouts.
Two large real-world studies find little separating tirzepatide and semaglutide
Head-to-head in US insurance data, the two drugs showed comparable cardiovascular outcomes and comparable rates of severe gastrointestinal events in type 2 diabetes. Neither study was a trial.